Holen Sie sich die Stockscreener-App
0.39
1.30%
0.005
Handel nachbörslich:
.38
-0.01
-2.56%
Schlusskurs vom Vortag:
$0.385
Offen:
$0.3834
24-Stunden-Volumen:
2.48M
Relative Volume:
0.81
Marktkapitalisierung:
$48.61M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.26
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
+8.88%
1M Leistung:
+9.95%
6M Leistung:
-82.43%
1J Leistung:
-85.92%
1-Tages-Spanne:
$0.3573
$0.39
1-Wochen-Bereich:
$0.303
$0.424
52-Wochen-Spanne:
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.39 | 44.94M | 36.86M | -171.67M | -171.05M | -1.50 |
|
ONC
Beigene Ltd Adr
|
236.86 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Mersana Therapeutics to Present at Upcoming Investor Conferences | MRSN Stock News - GuruFocus
Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | MRSN Stock News - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Mersana Therapeutics (MRSN) Reports Lower Q1 Revenue and Shares - GuruFocus
Mersana Therapeutics Provides Business Update and Announces Firs - GuruFocus
Mersana Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewswire
Clinical Trial Results: Mersana's New Cancer Drug Achieves 31% Response Rate in Hard-to-Treat Tumors - Stock Titan
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Barclays PLC Sells 311,805 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Wedbush Expects Stronger Earnings for Mersana Therapeutics - Defense World
Petri Dish: Cancer biotech cuts staff; Lantheus sells business unit - The Business Journals
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating - marketscreener.com
Mersana Therapeutics announces restructuring plans; shares fall - TradingView
Mersana Therapeutics Announces Restructuring and Reprioritization Plan - citybiz
Mersana Therapeutics (MRSN) Announces Major Restructuring Strate - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Repri - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer | MRSN Stock News - GuruFocus
Mersana Therapeutics announces strategic cutbacks amid economic pressures - Investing.com
Mersana Therapeutics Announces Strategic Restructuring to Extend Cash Runway and Focus on Emi-Le Development - Nasdaq
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewswire
Mersana Slashes Workforce by 55%, Doubles Down on Promising Breast Cancer Drug Pipeline - Stock Titan
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Mersana Therapeutics Inc [MRSN] stock for 2,061 USD was sold by Mandelia Ashish - knoxdaily.com
Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Mersana Therapeutics (MRSN) Expected to Announce Earnings on Thursday - Defense World
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):